CM24, a Novel Anti-CEACAM1 mAb, Suppresses Neutrophil Extracellular Trap (NET)-Induced Migration and Metastasis of Cancer Cells
in Nov 16, 2022
Presented at the AACR special conference: Cancer Metastasis, November, 2022
Interim Safety and Efficacy Results from a Phase 1 Study of NT219 in Adults with Advanced Solid Tumors
in Jun 16, 2022
Presented at the ASCO annual meeting 2022
Interim Safety and Efficacy Results from a Phase 1b Study of CM24 in Combination with Nivolumab in Adults with Advanced Solid Tumors
in Apr 15, 2022
Presented at the AACR annual meeting April, 2022
IRS1 phosphorylation underlies the non-stochastic probability of cancer cells to persist during EGFR inhibition therapy
in Oct 25, 2021
Published in Nature Cancer, October 2021
A Phase 1b Study of CM24 in Combination with Nivolumab in Adults with Advanced Solid Tumors, followed by a Phase 2a study of CM24 in Combination with Nivolumab in NSCLC, and in Combination with Nivolumab and nab-paclitaxel in Pancreatic Cancer
in Sep 29, 2021
Presented at the ESMO annual meeting 2021
A Phase 1 2 Study with Open Label, Dose Escalation Phase Followed by Single Arm Expansion at the Maximum Tolerated Dose to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of NT 219 Injection Alone and in Combination with Cetuximab in Adults with Advanced Solid Tumors and Head and Neck Cancer
in Jun 06, 2021
Presented at ASCO annual meeting 2021
Adaptation of Colorectal Cancer Cells to the Brain Microenvironment The Role of IRS2
in Apr 12, 2021
Presented at the AACR annual meeting 2021
A Phase 1 Open-label Multicenter Single Dose Escalation and Multi-dose Study of a mAb Targeting CEACAM1 in Subjects with Selected Advanced or Recurrent Malignancies
in May 01, 2020
Presented at the ASCO annual meeting 2020